Purpose of review The aim of this article was to review the recent literature on potential therapeutic strategies for overcoming resistance to antivascular endothelial growth factor drugs in ovarian cancer.
INTRODUCTION
The current standard frontline therapy of ovarian cancer consists of combination surgery and cytotoxic chemotherapy [1] . While inducing lasting clinical remission in some patients, progress has stagnated because of adaptive or inherent drug resistance and lack of specificity to mechanisms of disease progression. Angiogenesis plays a critical role in the pathogenesis of epithelial ovarian cancer (EOC), promoting tumor growth and metastatic spread [2] . To date, antiangiogenic therapy has been identified as one of the most promising targeted therapies in ovarian cancer and worthy of intensive study. The vascular endothelial growth factor (VEGF) family is among the most potent proangiogenic factors [3, 4] . Other angiogenic growth factors and chemokines include fibroblast growth factor, angiopoietins, endothelins, interleukin-8, macrophage chemotactic proteins, and platelet-derived growth factor (PDGF) [2, 5] . Many agents targeting these growth factors have produced clinical benefits in ovarian cancer [1,6 & ].
VASCULAR ENDOTHELIAL GROWTH FACTOR/VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TARGETED THERAPIES survival (PFS) when administered concomitantly with chemotherapy and in maintenance but without extending overall survival (OS) ( Table 1) [7-9,10 & , [11] [12] [13] [14] . A completed clinical trial AURELIA (A Study of Bevacizumab [Avastin] Added to Chemotherapy in Patients With Platinum-Resistant Ovarian Cancer) evaluated the efficacy and safety of bevacizumab added to chemotherapy vs. chemotherapy alone [chemotherapy alone (CT)] in patients with EOCs with disease progression within 6 months of platinum therapy. All patients received standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. The patients were randomly assigned to receive chemotherapy alone or chemotherapy combined with bevacizumab (15 mg/kg every 3 weeks or 10 mg/kg every 2 weeks) until progressive disease, unacceptable toxicity, or withdrawal of patient consent. Bevacizumab added to chemotherapy treatment resulted in a significant improvement in PFS compared with carboplatin and topotecan treatment [6.7 months with bevacizumab-containing therapy vs. 3.4 months with chemotherapy alone; hazard ratio (HR): 0.48; 95% confidence interval (CI): 0.38-0.60; P < 0.001] [7] . Another placebocontrolled phase III trial OCEANS (Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) tested the efficacy and safety of bevacizumab with gemcitabine and carboplatin compared with gemcitabine and carboplatin in platinum-sensitive recurrent ovarian cancer (ROC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) for 6-10 cycles; gemcitabine, and carboplatin with bevacizumab followed by bevacizumab until progression resulted in a statistically significant improvement in PFS compared with gemcitabine and carboplatin with placebo in platinum-sensitive (median PFS was 8.4 and 12.4 months for the gemcitabine and carboplatin with placebo and bevacizumab with gemcitabine and carboplatin arms, HR: 0.484; 95% CI: 0.388-0.605; P < 0.0001) [8] (Table 1 ). Bevacizumab has thus regulatory approval in many countries for this setting [7,15 & , [16] [17] [18] . Several combinations of bevacizumab with other antitumor agents have been tested. In a phase II study, the effect of combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced EOC was investigated. The 12-month PFS rate was 65.7% and median PFS was 16.3 months. Median OS was 47.3 months, indicating that this novel treatment regimen may provide a promising therapeutic approach [19] . Carboplatin and bevacizumab applied in a neoadjuvant setting resulted in optimal Interval cytoreductive surge (ICS) in all patients, in which 78% had no gross residual tumor [20] . In addition, bevacizumab showed activity in the treatment of recurrent sex cord-stromal tumors of the ovary with acceptable toxicity [21 & ]. The most common adverse events were neutropenia, leukopenia, hypertension, fatigue, nausea, proteinuria, and even fatal gastrointestinal perforation [22, 23] . A history of treatment for inflammatory bowel disease or bowel resection at primary surgery was found to increase the odds of gastrointestinal adverse events [24] .
SMALL MOLECULE INHIBITORS
Sorafenib is a nonselective multikinase inhibitor that has broad activity against tyrosine kinase receptors, including VEGF receptor (VEGFR) and PDGF receptor (PDGFR), as well as angiogenic factors [25 & ,26] . Modest activity, but with noted adverse effects, was observed when sorafenib was administered alone or combined with carboplatin and paclitaxel in several phase II trials [27] . One study that combined sorafenib with bevacizumab showed partial remission in 46% of patients and stable disease in 37% of patients [26] . However, a randomized phase II trial of sorafenib as a maintenance strategy failed to meet its primary endpoint of PFS [28] .
Nintedanib (BIBF 1120) is another tyrosine kinase inhibitor that targets VEGFR, PDGFR, and fibroblast growth factor receptor. In a phase II trial of patients with relapsed ovarian cancer, the PFS rate was 16.3% in the nintedanib arm vs. 5% in the placebo arm (HR: 0.65; 95% CI: 0.42-1.02; P ¼ 0.06). A significantly higher grade 3/4 hepatotoxicity was detected in nintedanib-treated patients than in the placebo arm (51.2% vs. 7.5%; P < 0.001).
In a phase III [Arbeitsgemeinschaft Gynakologische
Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)] 12 study, favorable results were reported (Table 1) [9] . Another planned phase II trial will
KEY POINTS
Anti-VEGF therapy has yielded modest improvements in PFS and OS.
Adaptive resistance and escape from antiangiogenesis therapy is multifactorial.
Controversy exists regarding when to start and end antiangiogenesis therapy as well as the choice of the optimal combination.
Predictive markers for response to antiangiogenesis therapy are needed. investigate nintedanib in bevacizumab-resistant, recurrent, or persistent ovarian cancer. The most common adverse events with tyrosine kinase inhibitor drugs included diarrhea, thrombocytopenia, hepatic toxicity, anemia, or even neuropathic syndrome [29] . Cediranib is a potent inhibitor of all receptors of the VEGF family, and has activity against PDGF-b and c-Kit with generally well tolerated adverse event [30] . A two-stage, multicenter phase II clinical trial was initiated to evaluate the activity of cediranib in patients with recurrent ovarian, peritoneal, or FTC. The median time to progression and median survival time for all patients was 4.1 (95% CI: 3.4-7.6) and 11.9 months (95% CI: 9.9 to not reached), respectively, which shows significant activity in recurrent ovarian cancer [31] . Cediranib combined with olaparib, a poly (adenosine diphosphate-ribose) polymerase inhibitor resulted in improved PFS (17.7 months, 95% CI: 14.7 to not reached, vs. 9.0 months, 95% CI: 5.7-16.5) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer [32] . In the International Collaborative Ovarian Neoplasm 6 trial (three-arm, three-stage, double-blind, placebo-controlled randomized trial in first relapse of platinumsensitive ovarian cancer), patients were randomized (2:3:3) to receive six cycles of carboplatin (AUC, target area under the concentration versus time curve in mg/mL Á min 5/6) and paclitaxel (175 mg/m 2 ) with either placebo (reference), cediranib 20 mg/day, followed by placebo (concurrent), or cediranib 20 mg/day, followed by cediranib (concurrent and maintenance). They reported longer restricted mean PFS and OS in the cediranib arm [33] (Table 1) .
Pazopanib (GW786034) is a second-generation pan-VEGFR, PDGFR-a and b, and c-Kit inhibitor [14] . In a phase II study, patients with EOC were treated with pazopanib; 11 patients (31%) had a cancer antigent 125 (CA-125) response to pazopanib, and the overall response rate was 18% [34] . However, another phase II study was discontinued because of the lack of activity of pazopanib in patients with recurrent EOC, PPC, or FTC [35] . In a recent randomized phase III trial (AGO-OVAR16), pazopanib showed a role in the treatment of selected women with EOC, especially use in women with bevacizumab-resistant disease ( Table 1) . Questions remain about optimal timing, the ideal patient population, and the efficacy of combination therapy with cytotoxic agents and other biologics.
Although clinical benefits of anti-VEGF therapy were observed in ovarian cancer, anti-VEGF therapy, however, has yielded only modest improvement in PFS or OS. The greatest challenge today is that a substantial number of patients with cancer eventually develop disease resistance to anti-VEGF therapy.
RESISTANCE MECHANISMS IN ANTIANGIOGENIC THERAPY
Evidence suggests that mechanisms of resistance to anti-VEGF therapy might be mediated by tumor cells and by members of the microenvironment [36] [37] [38] . Hypoxia is a major molecular controller of angiogenic switch [36, 39, 40] ; hypoxia inducible factor 1-a, and interleukin-8 expression have been shown to support angiogenesis and resistance to apoptosis [39] [40] [41] . It is known that VEGF pathway inhibition can cause hypoxia and promote recruitment of vascular progenitors (e.g., endothelial and pericyte progenitors) and vascular modulators [tumor-associated macrophages (TAMs), immature monocytes, VEGFR-1 hemangiocytes, and CD11bmyeloid cells]. This environment favors selection of tumor clones expressing proangiogenic factors such as Bv8, which has been shown to be partially responsible for angiogenesis promotion, and escape from VEGF blockade. In addition, hypoxia was demonstrated to drive translocation of MDM2 to the cytoplasm, with binding and stabilization of VEGF mRNA [42] .
Growing evidence indicates that inflammation controls angiogenesis. Tumor-infiltrating myeloid cells including neutrophils, eosinophils, and activated dendritic cells play a crucial role in ovarian cancer progression [39] . Myeloid leukocytes were recently shown to drive both inhibition of tumor growth (first) and aggressive malignant expansion (later). CD11bþGr1þ myeloid-derived suppressor cells confer resistance to initially sensitive tumors. In one study, myeloid cell-driven angiogenesis was selectively ablated in a mouse model of breast cancer, resulting in reduced VEGF, reduced vascular density, and increased blood vessel maturation and normalization.
Infiltrating TAMs and enrichment of a macrophage-related gene signature are associated with cancer progression and escape from antiangiogenic therapy in several types of human cancer [40, 43] . TAMs of the M2 phenotype promote tumor vascularization by producing proangiogenic and growth factors, including transforming growth factorb and VEGF, and attracting leukocytes to further enhance angiogenesis [43, 44] . Depletion of these macrophages reduces angiogenesis and tumor progression.
Pericytes are smooth muscle-like cells found in close contact with endothelial cells in small blood vessels and capillaries; these functionally associate with regulating vessel stabilization, providing endothelial survival factors, such as VEGF. Immature vessels with poor pericyte investment are vulnerable to anti-VEGF treatment, while richer pericyte coverage may protect vessels from VEGF-targeted therapy [45] . VEGF blockade increases the signaling of angiopoietin-1, resulting in improved endothelial cell function and pericyte recruitment, which in turn is implicated in the rescue and escape from VEGF blockade [45] .
TARGETING OTHER PATHWAYS BEYOND THE VASCULAR ENDOTHELIAL GROWTH FACTOR/VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PATHWAY
Several proangiogenic molecules and mechanisms underlying angiogenesis beyond the VEGF/VEGFR pathway such as delta-like ligand (Dll)4/notch, focal adhesion kinase (FAK) and microRNAs (miRNAs) have been recognized ( Fig. 1) [46] . The notch signaling pathway is comprised of five transmembrane notch ligands (jagged 1, jagged 2, and Dlls 1, 3, and 4) and four notch receptors (notch 1-4) [47] . We have demonstrated that notch pathway alterations, especially in Notch3 (amplification or upregulation of expression), are prevalent in high-grade serous ovarian cancer (HGS-OvCa) and are associated with shorter OS [48] . Dll4 is an endothelium-specific ligand expressed at sites of vascular development and angiogenesis. Blockage of Dll4 inhibits tumor growth by inducing nonproductive angiogenesis, manifested by increased vascular density and decreased perfusion in tumors [47, 49] . We investigated the clinical and biological significance of Dll4 in ovarian cancer and found that Dll4 was overexpressed in 72% of tumors examined where it was also an independent predictor of poor survival. Patients with tumors responding to anti-VEGF therapy had lower levels of Dll4 than patients with stable or progressive disease. Dll4 silencing in ovarian tumor cells and associated endothelial cells inhibited tumor growth and angiogenesis [50] . Clinical enthusiasm in targeting the Dll4/notch signaling pathway is high, particularly with the availability of g-secretase inhibitors and anti-Dll4 antibodies (demcizumab and REGN 421, available at http://clinicaltrials.gov).
FAK is a 125-kDa nonreceptor kinase. VS-6063 is a FAK inhibitor that blocks phosphorylation at the Tyr397 site. Combination of VS-6063 and paclitaxel markedly decreased proliferation and increased apoptosis [51] . FAK silencing in combination with docetaxel resulted in decreased microvessel density, increased apoptosis, and reduced tumor growth.
MiRNAs are small noncoding RNAs (21-23 nt) that regulate gene expression through translational repression and mRNA degradation. Recent studies have shown that few miRNAs are involved in the regulation of vascular development and angiogenesis. MiR-10b and miR-196b have been identified to promote angiogenesis by directly regulating bone marrow-derived endothelial progenitor cells, whereas miR-126 induces angiogenesis by increasing VEGF expression. Conversely, miR-221 and miR-222 inhibit angiogenesis by targeting c-Kit receptors in endothelial cells. MiR-718 directly represses VEGF expression and inhibits ovarian cancer proliferation both in vitro and in vivo [52 & ]. The miR-200 family inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1, whereas overexpression of miR-199a and miR-125b inhibited angiogenesis associated with the decrease of hypoxia inducible factor 1-a and VEGF expression in EOC cells [53] .
NOVEL ANGIOGENESIS-TARGETED THERAPY
Growing evidence suggested that adaptive resistance and escape from antiangiogenesis therapy is likely a multifactorial process, including induction of hypoxia, vascular modulators, and immune response. New drugs targeting the tumor vasculature or other components of the surrounding microenvironment have shown promising results. 
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ANGIOPOIETIN INHIBITORS
Angiopoietin-1 is critical for vessel maturation, adhesion, migration, and survival. Angiopoietin-2 differentially regulates angiogenesis through Tie2 and integrin signaling [54, 55] . Trebananib (AMG 386) is a peptide-Fc fusion protein (or peptibody) that targets angiogenesis by inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor [56, 57] . Combined inhibition of angiopoietin-1 and 2 may provide superior therapeutic efficacy to that mediated by single targeting alone [58 & ]. In several phase I trials, objective responses were demonstrated in patients with advanced ovarian cancer treated with trebananib alone or in combination with chemotherapy [59] . A phase II randomized trial has evaluated weekly paclitaxel and trebananib in 161 patients with recurrent EOC. A significantly improved median PFS with trebananib was reported than placebo (HR: 0.76; 95% CI: 0.52-1.12; P ¼ 0.165), with evidence of a significant doseresponse effect (P ¼ 0.037) [57, 59] ,60]. LC06 is a novel angiopoietin-2 selective human antibody with potent antitumoral and antiangiogenic efficacy and had a superior adverse event profile compared to pan-angiopoietin-1/2 inhibitors. LC06 neutralizes specifically the binding of angiopoietin-2 to its receptor Tie2, and the inhibition appears to be largely restricted to tumor vasculature without obvious effects on normal vasculature [61] .
RNA INTERFERENCE APPROACHES
Early-phase trials have reported clinical responses in patients with cancer after RNA interference therapies targeting VEGF and kinesin spindle protein.
The results showed target downregulation and antitumor activity in regression of liver metastases. We have demonstrated that EZH2 silencing in the tumor vasculature results in antiangiogenic and antitumor effects [62] . Vasohibin-2 small interfering RNA (siVASH2) targeted to a xenograft model of ovarian cancer significantly inhibited tumor growth by abrogating tumor angiogenesis [63 & ]. We have also demonstrated the feasibility of combined miRNA-small interfering RNA (siRNA) therapy in preclinical models. Synergistic antitumor efficacy was noted with miR-520d-3p combined with ephrin type-A receptor 2 (EphA2)-siRNA using dioleoyl phosphatidylcholine (DOPC) nanoliposomes [64 & ]. Studies to address the safety and efficacy of several siRNA, CALAA-01 [65] , TKM 080301 [66] , and siRNA-(ephrin type-A receptor 2) EphA2-(dioleoyl phosphatidylcholine) DOPC (NCT01591356) [67] in solid tumors and their liver metastasis are ongoing.
TARGETING MACROPHAGES
TAM depletion by clodrolip or a CSF1R inhibitor increased the antiangiogenic and antitumor effects of VEGF/VEGFR2 antibodies in subcutaneous tumor models. Depletion of macrophages by zoledronic acid in combination with sorafenib significantly inhibited tumor progression and tumor angiogenesis compared with mice treated with sorafenib alone [68] . These data support the rationale for combining antiangiogenic drugs with macrophage targeting strategies to increase the efficacy of the former, particularly in tumors that are refractory or develop resistance to anti-VEGF therapy.
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that has been reported to promote tumor progression and enhance angiogenesis [69] . MIF levels in serum of patients with ovarian cancer correlates with poor prognosis [70] . Current therapeutic strategies for targeting MIF mainly focus on developing small inhibitors [ISO-66, an analog of ISO-1 (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1)] toward its tautomerase activities or biologic activities [71 & ].
CONCLUSION
To improve the therapeutic benefit and counteract compensatory escape mechanisms, it is likely that simultaneous targeting of multiple angiogenic pathways will be required [72] . Additional studies are necessary to determine optimal combinations that could involve either vertical (e.g., bevacizumab with other angiogenesis inhibitors such as sorafenib [31] , vandetanib [73] , sunitinib [74] ), horizontal [e.g., inhibitors of Phosphoinositide 3-kinase (PI3K) pathway , Mitogen-activated protein kinase (MEK), immune, and angiopoeitin], or direct [e.g., bevacizumab with thrombospondin-1 [75] or vascular disrupting agents such as combretastatin A1 phosphate (OXi4503)] [76] .
